search
Back to results

Antiplatelet Therapy After Cardiac Arrest

Primary Purpose

Cardiac Arrest, Postresuscitation Syndrome, Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)

Status
Completed
Phase
Phase 4
Locations
Slovenia
Study Type
Interventional
Intervention
Clopidogrel
Ticagrelor
Sponsored by
University Medical Centre Ljubljana
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiac Arrest focused on measuring Antiplatelet Therapy, Cardiac Arrest, Therapeutic hypothermia, Myocardial infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Female and male over 18 years old
  • Unconscious survivors of cardiac arrest treated with therapeutic hypothermia
  • Acute coronary syndrome (NSTEMI or STEMI) as a reason of cardiac arrest
  • PCI with stent implantation
  • Provision of informed consent prior to any study specific procedures is impossible because subjects are unconscious at the moment of inclusion

Exclusion Criteria:

  • Use of any P2Y12 inhibitors in last 10 days
  • Use of prasugrel before and 48 hours after loading dose of P2Y12 inhibitor
  • Use of eptifibatide before and 48 hours after loading dose of P2Y12 inhibitor
  • Thrombocytopenia (<50*109/L)
  • Allergic reaction to acetylsalicylic acid, clopidogrel or ticagrelor
  • Ticagrelor contraindications: previous intracranial bleeding, active pathological bleeding, moderate to severe hepatic impairment, heart rate < 40/min at presentation
  • Suspected or confirmed pregnancy
  • Use of bivalirudin before and 48 hours after loading dose of P2Y12 inhibitor

Sites / Locations

  • University Medical Centre Ljubljana

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Clopidogrel

Ticagrelor

Arm Description

These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.

These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.

Outcomes

Primary Outcome Measures

VerifyNow P2Y12Test - Platelet Reactivity
Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as >208 PRU.

Secondary Outcome Measures

VerifyNow P2Y12Test - % Inhibition
% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as <11% inhibition.
Multiplate ADP Test
Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets. High on-treatment platelet reactivity was defined as >46 U.

Full Information

First Posted
August 19, 2014
Last Updated
October 17, 2018
Sponsor
University Medical Centre Ljubljana
search

1. Study Identification

Unique Protocol Identification Number
NCT02224274
Brief Title
Antiplatelet Therapy After Cardiac Arrest
Official Title
Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
August 2014 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
June 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Medical Centre Ljubljana

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
There is growing evidence that standard dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel is not as effective in the setting of therapeutic hypothermia after cardiac arrest as in normothermic patients. The reasons for this are probably slower gastrointestinal motility, absorption and liver metabolism required for clopidogrel to take action. Since ticagrelor has faster intestinal absorption and no need for liver metabolism we expect its effect to be good even in patients with therapeutic hypothermia after cardiac arrest. Patients treated with therapeutic hypothermia after cardiac arrest and percutaneous coronary intervention will be randomised into two groups. One will be treated with ASA and clopidogrel and the other with ASA and ticagrelor. Blood samples will be collected before and 2, 4, 12, 22 and 48 hours after P2Y12 inhibitor administration. Platelet function will be measured by VerifyNow P2Y12 assay and by Multiplate ADPTest. Differences between the groups will be analysed. Hypothesis: Antiplatelet therapy with ticagrelor is more effective than therapy with clopidogrel in the comatose survivors of cardiac arrest treated with therapeutic hypothermia and percutaneous coronary intervention (PCI).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Arrest, Postresuscitation Syndrome, Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)
Keywords
Antiplatelet Therapy, Cardiac Arrest, Therapeutic hypothermia, Myocardial infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
57 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Clopidogrel
Arm Type
Active Comparator
Arm Description
These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.
Arm Title
Ticagrelor
Arm Type
Experimental
Arm Description
These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.
Intervention Type
Drug
Intervention Name(s)
Clopidogrel
Other Intervention Name(s)
Clopidogrel (Plavix)
Intervention Type
Drug
Intervention Name(s)
Ticagrelor
Other Intervention Name(s)
Ticagrelor (Brilique)
Primary Outcome Measure Information:
Title
VerifyNow P2Y12Test - Platelet Reactivity
Description
Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as >208 PRU.
Time Frame
12 h after P2Y12 inhibitor loading
Secondary Outcome Measure Information:
Title
VerifyNow P2Y12Test - % Inhibition
Description
% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as <11% inhibition.
Time Frame
12 hours after P2Y12 inhibitor loading
Title
Multiplate ADP Test
Description
Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets. High on-treatment platelet reactivity was defined as >46 U.
Time Frame
12 hours after P2Y12 inhibitor loading

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female and male over 18 years old Unconscious survivors of cardiac arrest treated with therapeutic hypothermia Acute coronary syndrome (NSTEMI or STEMI) as a reason of cardiac arrest PCI with stent implantation Provision of informed consent prior to any study specific procedures is impossible because subjects are unconscious at the moment of inclusion Exclusion Criteria: Use of any P2Y12 inhibitors in last 10 days Use of prasugrel before and 48 hours after loading dose of P2Y12 inhibitor Use of eptifibatide before and 48 hours after loading dose of P2Y12 inhibitor Thrombocytopenia (<50*109/L) Allergic reaction to acetylsalicylic acid, clopidogrel or ticagrelor Ticagrelor contraindications: previous intracranial bleeding, active pathological bleeding, moderate to severe hepatic impairment, heart rate < 40/min at presentation Suspected or confirmed pregnancy Use of bivalirudin before and 48 hours after loading dose of P2Y12 inhibitor
Facility Information:
Facility Name
University Medical Centre Ljubljana
City
Ljubljana
ZIP/Postal Code
1000
Country
Slovenia

12. IPD Sharing Statement

Citations:
PubMed Identifier
24800722
Citation
Steblovnik K, Blinc A, Bozic-Mijovski M, Kranjec I, Melkic E, Noc M. Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia. EuroIntervention. 2015 Apr;10(12):1418-24. doi: 10.4244/EIJY14M05_02.
Results Reference
background
PubMed Identifier
23890998
Citation
Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013 Aug 17;382(9892):614-23. doi: 10.1016/S0140-6736(13)61170-8. Epub 2013 Jul 26. Erratum In: Lancet. 2014 Mar 29;383(9923):1128.
Results Reference
background
PubMed Identifier
19923168
Citation
Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009 Dec 22;120(25):2577-85. doi: 10.1161/CIRCULATIONAHA.109.912550. Epub 2009 Nov 18.
Results Reference
background
PubMed Identifier
17161902
Citation
Gorjup V, Radsel P, Kocjancic ST, Erzen D, Noc M. Acute ST-elevation myocardial infarction after successful cardiopulmonary resuscitation. Resuscitation. 2007 Mar;72(3):379-85. doi: 10.1016/j.resuscitation.2006.07.013. Epub 2006 Dec 11.
Results Reference
background
PubMed Identifier
11856794
Citation
Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002 Feb 21;346(8):557-63. doi: 10.1056/NEJMoa003289.
Results Reference
background
PubMed Identifier
23591428
Citation
Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos K, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Response to letter regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction". Circ Cardiovasc Interv. 2013 Apr;6(2):e29. doi: 10.1161/CIRCINTERVENTIONS.113.000134. No abstract available.
Results Reference
background
PubMed Identifier
22890586
Citation
Souckova L, Opatrilova R, Suk P, Cundrle I Jr, Pavlik M, Zvonicek V, Hlinomaz O, Sramek V. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013 Mar;69(3):309-17. doi: 10.1007/s00228-012-1360-0. Epub 2012 Aug 14.
Results Reference
background
PubMed Identifier
20727659
Citation
Bjelland TW, Hjertner O, Klepstad P, Kaisen K, Dale O, Haugen BO. Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2010 Dec;81(12):1627-31. doi: 10.1016/j.resuscitation.2010.07.002. Epub 2010 Aug 19.
Results Reference
background
PubMed Identifier
19535947
Citation
Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009 Jul;37(7 Suppl):S186-202. doi: 10.1097/CCM.0b013e3181aa5241.
Results Reference
background

Learn more about this trial

Antiplatelet Therapy After Cardiac Arrest

We'll reach out to this number within 24 hrs